HOME >> BIOLOGY >> NEWS
Liver transplant patients gain same benefits from CellCept as kidney transplant patients

25th May 2005, Basel, Switzerland New data reported in over 90 abstracts presented at the American Transplant Congress in Seattle show that liver transplant patients taking the immunosuppressant CellCept are gaining the same positive benefits already demonstrated in kidney transplant patients. This is good news for patients as the demand for liver transplants is increasing, with many of the cases directly resulting from chronic hepatitis C virus (HCV) infection.

Benefits seen with CellCept include:

  • Reduced risk of acute rejection, especially in patients infected with HCV
    • graft rejection is of particularly high risk in HCV patients and is associated with increased morbidity and decreased patient and graft survival (Abstract 928)

  • Safe and effective steroid-free regimens for HCV patients
    • steroids are known to have a negative impact on the progression of HCV, which can result in liver fibrosis (Abstract 475)

  • Optimal kidney function
    • CellCept taken with a low dose of tacrolimus showed a trend towards improved kidney function (Abstract 1240). CellCept is proven to promote excellent kidney function early after kidney transplantation in renal patients taking tacrolimus(1)

  • Less liver fibrosis
    • recipients taking CellCept-based regimens showed a significant reduction in the inflammation and structural changes that can lead to liver failure (Abstract 1446)

  • No increased risk of malignancy
    • the addition of CellCept to maintenance immunosuppression that includes tacrolimus and corticosteroids did not increase the risk of death due to malignant complications (Abstract 930). This confirms previous data as seen in kidney transplant recipients(2)

"It's really exciting to see liver transplant recipients benefiting from CellCept in the same way as kidney transplant patients.
'"/>

Contact: Vicky Singlehurst
vicky.singlehurst@ketchum.com
+44-207-611-3523
Ketchum
25-May-2005


Page: 1 2

Related biology news :

1. Liverpool amongst first in UK to install unique DNA sequencing technology
2. University of Liverpool launches 10 million small animal teaching hospital
3. Liverpool scientists work to improve water quality in Ghana
4. Liver regeneration may be simpler than previously thought
5. 2.5M boost for marine biology in Liverpool
6. Liver signal critical for insulins brain action
7. International scientists to present MRSA research in Liverpool
8. UC Davis, Lawrence Livermore researchers
9. Liver cancer linked to cellular repair pathway
10. Liver metabolism goes to pot
11. Liverpool vet creates pain relief diet for arthritic dogs

Post Your Comments:
(Date:8/21/2014)... skin fungus linked to dandruff, eczema and other itchy, ... even further global reachesincluding Hawaiian coral reefs and the ... , A review in the scientific journal PLOS ... the fungi of the genus Malassezia in ... datasets from around the world. , University of Hawai,i ...
(Date:8/21/2014)... Mller the Fram Strait is a key region in the ... between Greenland and Svalbard warm Atlantic water flows to the ... cold Arctic water masses and sea ice push their way ... portion of the Atlantic water cools here on its way ... of the water caused in this manner drives the global ...
(Date:8/21/2014)... researchers at Louisiana Tech University has developed ... 3D printers and materials to fabricate custom ... chemotherapeutic compounds for targeted drug delivery. , ... research faculty from Louisiana Tech,s biomedical engineering ... filament extruders that can make medical-quality 3D ...
Breaking Biology News(10 mins):From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3
(Date:8/22/2014)... , Aug. 22, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... periods ended June 30, 2014.  Biorem,s complete 2014 second quarter financial statements ... Financial Summary:Three-months ended June 30, , Six-months ended ... 2014 , 2013 , 2014 , ... 4,433 , 9,195 Gross profit , 56 , ...
(Date:8/22/2014)... Ophthalmic drug delivery technologies or ... endeavors as the anatomy, physiology and biochemistry of ... foreign substances. Ocular drug delivery technologies provide several ... minimal use of needles; also it enables high ... specific targeting within the ocular globe. On the ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Nerium ... products, is in the spotlight again. Nerium will ... and its NeriumFirmTM Body Contouring Cream to Hollywood’s ... Backstage Creations during the 66th Primetime Emmy® Awards. ... NAE-8® extract, third-party clinical trials show that NeriumAD ...
(Date:8/21/2014)... at the Institute for Molecular Medicine Finland (FIMM), ... developed a novel "man and machine" decision support ... aid was described in PLOS One ... based on computer vision algorithms similar to those ... of only the diagnostically most relevant areas. Tablet ...
Breaking Biology Technology:Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 3A novel 'man and machine' decision support system makes malaria diagnostics more effective 2
Cached News: